Isomorphic Labs secures $5 billion for AI drug candidates

Isomorphic Labs closes a $5 billion Series C
Isomorphic Labs, the AI drug-discovery company spun out of Google DeepMind in 2021, has raised $5 billion in a Series C round as it works to move drug candidates into clinical trials. Greenoaks and Sequoia Capital co-led the financing, while new investor Andreessen Horowitz and other investors also participated.
Existing investors also joined the round, including Alphabet venture arms GV and Capital G, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund. Isomorphic Labs did not disclose a new valuation. Bloomberg had reported earlier in the month that the company was seeking funding at a $50 billion valuation.
The financing follows a $2.1 billion Series B completed in May. Isomorphic Labs said the new capital will fund further development of its drug-design engine and support expansion into additional types of medicine.
Simulation models underpin the drug-design platform
Isomorphic Labs develops an AI drug-design engine based on multiple simulation models that explore different areas of chemistry to help design drugs. Its work draws on AlphaFold, DeepMind's protein-folding system that predicts a protein's three-dimensional structure from its genetic sequence.
The company said its programmes have generated positive preclinical results in oncology and immunology. It has also entered into deals with Eli Lilly, Novartis and Johnson & Johnson, placing the platform alongside established pharmaceutical development efforts.
Leadership focus shifts toward drug discovery
The Series C is the company's first funding round since founder and chief executive Demis Hassabis left his role as head of DeepMind to focus on drug discovery and became chairman of DeepMind. Hassabis and former DeepMind director John Jumper received the Nobel Prize in chemistry for the laboratory's AlphaFold work.
For businesses assessing AI in life sciences, the round highlights the distinction between research capability and clinical development: Isomorphic Labs is directing new capital toward taking candidates beyond preclinical results and into trials.

